Articles tagged with Drug Therapy
Researchers explore using human pluripotent stem cells to identify cardiotoxicity risks in patients taking chemotherapy agents and other drugs. This approach may boost the number of successful clinical trials for cardiovascular disease treatments.
CVT-301, an inhaled form of levodopa, is being studied for its potential to restore motor function in people with Parkinson's disease experiencing OFF periods. The Phase 3 clinical program aims to confirm the efficacy and safety profile of CVT-301.
Researchers have developed a new platform using whole animal models that can speed up scientific research and accurately assess the effectiveness of new drugs for neurodegenerative diseases. The platform, which uses roundworms, can analyze thousands of live animals simultaneously and at high speeds.
A new study by the NIH found that even partial steroid treatment can have significant benefits for extremely premature infants. The research showed that infants exposed to partial treatment in the womb had better outcomes than those not exposed, with lower rates of brain and nervous system impairment.
A pooled analysis of 16 prospective multicenter trials found financial difficulties associated with a 35% greater risk of worse global quality-of-life response and a 20% increase in risk of death. Financial burden was present in 26% of patients at baseline, and worsening financial problems during treatment increased mortality risk.
A study found that juvenile offenders with PTSD are at a 67% greater risk of entering substance abuse treatment within seven years. The research suggests that clinicians can expect most young offenders who need treatment to have experienced serious emotional or physical trauma.
Researchers at the University of Pittsburgh School of Medicine identified a unique 'constrained motion' pattern in which Rad4, a repair protein, scans DNA for structural faults. This discovery could lead to therapies that enhance existing treatments and counter drug-resistance, particularly in cancer.
A clinical trial found that ruxolitinib, a JAK inhibitor, significantly restored hair growth in 75% of patients with moderate to severe alopecia areata. The treatment was well-tolerated and showed promise for treating other forms of hair loss.
A new study found that patient-centered care was associated with improvements in physical and mental quality of life, as well as some aspects of diabetes self-management. However, the study did not show a significant effect on glycemic control.
Researchers have identified two key symptoms that make it harder for depressed smokers to quit: low positive affect and cognitive impairment. A new treatment approach, combining Chantix with behavioral activation therapy, is being tested to target these challenges.
A three-armed clinical trial found that spinal manipulation therapy reduced migraine days, but the effect was likely attributed to a placebo response. Migraine treatment with usual drug therapy failed to show sustained benefits.
A new study found that working memory dysfunctions and depression are predictors of non-adherence to oral cancer therapies. The research highlights the importance of assessing cognitive functions before initiating treatment to identify patient profiles at risk of non-adherence.
A new study has found that adalimumab (Humira) is an effective, non-steroid alternative for treating eye inflammation in patients with non-infectious uveitis. The medication targets a protein that promotes inflammation, delaying treatment failure and reducing symptoms.
Researchers found that a simple saline solution twice daily was just as effective as three medications in reducing the frequency and severity of chronic nosebleeds. The study's results suggest that simple hydration may be enough to prevent nosebleeds, making saline nasal spray a potential treatment option.
Two studies found that nasal sprays containing bevacizumab, estriol, or tranexamic acid failed to significantly reduce the frequency and duration of nosebleeds in patients with hereditary hemorrhagic telangiectasia. The treatment also had no measurable effect on quality of life, hemoglobin levels, or red blood cell transfusions.
The use of glutathione for skin bleaching is on the rise in the UK despite potential risks and lack of regulation. The practice has been linked to serious side effects such as Stevens Johnson syndrome and toxic epidermal necrolysis, as well as transmission of infectious diseases like HIV and hepatitis.
Researchers have discovered a nanotech-based delivery system that can carry the new drug into cells more effectively, improving its efficacy and allowing lower doses. This treatment shows promise for treating 50+ genetic disorders requiring brain targeting.
Researchers found a mixture of HER2-positive and HER2-negative breast cancer cells in patients' blood samples, which can lead to tumor progression and resistance to treatment. Combining therapies targeting both populations may be effective in eliminating these cells.
A systematic review of existing research suggests that physical activity could divert attention away from addiction, build confidence, and improve mood. The study aims to provide practical information on the effectiveness of physical activity as an alternative approach to treating alcohol and substance use disorders.
Researchers at the University of Washington extended the lives of middle-aged mice by up to 60% with a brief rapamycin treatment. The study also highlights the need to understand how dose and gender influence side effects, revealing potential benefits for humans, particularly older adults.
A study published in JAMA Surgery found that few studies included men and women equally, with wide variation in inclusion and matching of the sexes among specialties and journals. This sex bias can lead to different postoperative outcomes, complication rates, and readmission rates for males and females.
Researchers at Aarhus University Hospital found a molecule associated with Oxaliplatin treatment resistance, where patients with high levels have a six times higher risk of not responding to the drug. Eliminating this microRNA biomarker from tumors may restore sensitivity to Oxaliplatin-based chemotherapy.
A new study reveals that physician and nurse collaboration is vital for referring patients to integrative therapies, such as massage and acupuncture, while hospitalized. The research found that nurses play a key role in recommending these services.
A long-term study found that starting medication for multiple sclerosis at the earliest sign of the disease can prolong the time before a definitive diagnosis is made. Participants who received early treatment had 33% fewer diagnoses of MS, more time between relapses, and lower yearly relapse rates compared to those on delayed treatment.
Researchers at Charité - Universitätsmedizin Berlin have successfully treated two patients with rare genetic disorders causing severe hyperphagia. The new drug treatment, which targets the satiety center in the brain, resulted in significant weight loss and normalization of hunger feelings in both patients.
A recent study published in The Lancet Oncology found that adults with slow-growing kidney cancer can live for months or even years without worsening disease progression through active surveillance. The approach was most successful in patients with limited metastatic disease and fewer risk factors.
A new study examines Zika virus' effect on neuronal cells and its link to Guillain-Barré syndrome. Researchers highlight the need for further research on mechanisms underlying neurological complications and diagnostic criteria for microcephaly.
A University of Illinois research project is examining the effectiveness of Mindfulness Based Relapse Prevention (MBRP) in helping young adults stay sober after substance use treatment. MBRP targets negative emotions and cravings, fostering greater tolerance of stress and reducing relapse.
A new study found that immunosuppressive drugs can alter visual performance in rats, which are commonly used for translational stem cell research. The findings have important implications for interpreting results of studies using these models.
Researchers at ANU have found that changes in the protein enable the parasite to evade some drugs but make it vulnerable to others. This discovery could prolong the use of anti-malarial drugs, including chloroquine, and improve cure rates for people with malaria.
Recent studies support the use of spinal cord stimulation (SCS) as a safe and effective treatment for chronic back and limb pain. SCS uses low-voltage electrical stimulation to block pain signals via a small device implanted in the body.
The study found that both aripiprazole and quetiapine were effective in improving symptoms of schizophrenia, particularly positive symptoms. However, aripiprazole demonstrated slightly better efficacy in general psychopathology and insight. No significant increase in extrapyramidal adverse effects was observed in either group.
Researchers reviewed polypharmacological drugs for their role in treating epilepsy, highlighting their potential as broad-spectrum anticonvulsants. These medications have been shown to reduce seizure episodes and improve quality of life by targeting multiple pathways involved in the disorder.
Autoinflammatory diseases are characterized by recurrent acute inflammatory episodes due to deregulation of the inflammatory process. Researchers have identified epigenetic alterations in cryopyrin-associated periodic syndromes (CAPS), which could lead to the development of novel biomarkers for diagnosis and treatment.
A study by Jennifer Estall and Aurèle Besse-Patin explores how female mice respond to FGF21, a hormone that improves metabolism and insulin sensitivity. The researchers aim to provide a more comprehensive understanding of the effect of sex on drug treatment for metabolic diseases.
Researchers propose a novel combination therapy using resveratrol, antioxidants and iron chelators to slow down Alzheimer's disease progression. The addition of resveratrol may enhance cell viability and longevity by activating AMPK and sirtuin pathways.
Researchers at the University of Iceland have developed several new formulations for topical treatments of oral mucosal conditions. Topical application of doxycycline was effective in promoting healing of mucosal lesions, while monocaprin reduced counts of Candida rapidly and significantly.
Researchers developed mini-gut organoids from cystic fibrosis patient cells to screen drugs and personalize treatment. The mini-guts responded to CFTR-targeting therapies in vitro, correlating with clinical trial data and paving the way for tailored treatments.
The study found that patients who received the LINKAGE intervention had greater involvement in managing their health and healthcare than those receiving standard care. Participants showed significant increases in patient portal use and rates of abstinence from alcohol and drugs.
Researchers at Johns Hopkins Medicine have developed a new blood test to measure levels of hematoma-derived growth factor (HDGF), which rise predict survival in patients with severe pulmonary arterial hypertension. Higher levels of HDGF are linked to more extensive heart failure and poorer outcomes.
ADHD prescriptions in UK children increased over two decades but have levelled off since 2008. Treatment tends to last longer in the UK than in other countries.
A genetic blood test called NETest measures specific genes in the blood that define and predict responsiveness to PRRT. The test was found to be more than 90% accurate in predicting therapy response and non-response, with 73% of low-grade tumors responding to treatment.
A study by Cornell University researchers found genetic links between horse immune function and the papillomavirus that causes sarcoid skin tumors. The findings suggest a complex mix of virus, host genes, and tumor development, with relevance to related human conditions like cervical cancer.
Experts argue that integrated treatment could lead to a 40% reduction in implementation costs and be cost-effective in treating school-aged children and entire communities. The authors emphasize the need for increased drug subsidies, donations from pharmaceutical companies, and improved epidemiological surveillance.
Researchers at University College London have successfully targeted an autoimmune condition in mice using cancer drugs being tripped in human patients. The study found that by blocking a specific genetic key, the immune system's aggressive response could be prevented, reducing inflammation and damage.
Researchers have developed nanoparticles that can selectively deliver drugs to inflamed joint tissue, improving tolerability and reducing treatment costs. This breakthrough offers new hope for patients with rheumatoid arthritis, allowing for early diagnosis and targeted therapy.
Researchers found that expensive drugs like aflibercept are not cost-effective for treating diabetic macular edema compared to cheaper alternatives. To reach a threshold of $100,000 per quality-adjusted life-year, treatment costs would need to decrease by 69% for aflibercept and 80% for ranibizumab.
A study found that patients with rheumatoid arthritis (RA) who are positive for the anti-CCP antibody respond better to abatacept, a T cell co-stimulation blocker. In contrast, patients without this antibody do not show significant differences in treatment response to TNF inhibitors.
Faulty assumptions about addressing minority patients' needs underlie persistent racial/ethnic disparities in mental health and substance use disorders. The article recommends tailoring care, responding to patient needs, and expanding the workforce to reduce disparities.
A study presented at EULAR 2016 found that patients with antibodies to biological infliximab are less likely to benefit from infliximab biosimilar (CT-P13). The presence of these anti-infliximab antibodies can lead to a loss of response and increased risk of side effects. The findings suggest that antibody-positive patients should not ...
A survey of over 3,600 adults with RA found that patients value patient participation in multidisciplinary team conferences, leading to better outcomes. Patients want more involvement in treatment planning, with 70% satisfied but desiring fewer medications and more choices.
Researchers identified a lymphatic endothelium origin for angiomyolipoma and lymphangioleiomyomatosis, two related tumors with previously unknown cellular origins. The study suggests a potential novel origin for LAM mechanistically dependent upon TSC inactivation as well.
Researchers developed a predictive model that uses patient-specific stem cells and genetic data to forecast heart defect types in pediatric patients. The model was tested on human cardiomyocyte cells from patients with specific mutations, achieving accurate predictions of hypertrophic or dilated cardiomyopathy.
Research suggests that melanomas from the South Island of New Zealand are more likely to carry gene mutations affecting treatment outcomes. The study found significantly higher rates of NRAS mutations in South Island patients compared to those from the North Island, with implications for targeted drug therapies and patient outcomes.
Researchers at Texas Tech University Health Sciences Center have discovered that the intracellular domain of serotonin type 3A receptors can assemble into stable pentamers, suggesting a new approach to treating diseases such as epilepsy, anxiety, and Alzheimer's. This breakthrough may enable targeted therapies without undesired effects.
Researchers found that pre-treatment with an Alk5 inhibitor enhances the delivery of ferumoxytol to tumors, allowing for improved imaging. The study demonstrates potential for Alk5 inhibitors to improve tumor imaging and diagnosis of solid tumors.
A study compared four PD-L1 IHC diagnostic assays in lung cancer, demonstrating similarities and differences. The findings support the use of each assay according to its specific indication, recommending utilization for distinct scoring algorithms.
Researchers have identified gene variants associated with a serious adverse reaction to antithyroid drugs used for hyperthyroidism treatment. The study found that certain immune genes increase the risk of agranulocytosis, a life-threatening condition.
A recent NIH-funded study found that half of patients with age-related macular degeneration (AMD) maintained 20/40 vision or better after five years of anti-VEGF drug treatment. The study also showed that the two most commonly used drugs, Avastin and Lucentis, were equally effective in preserving visual acuity.
A Penn-coordinated study confirms that half of patients with age-related macular degeneration retain 20/40 vision or better after five years of treatment with Avastin or Lucentis. The study also found signs of modestly worsening disease, but overall, the therapy has shown significant benefits in slowing vision loss.